Heavyweights Apple Inc <AAPL.O>, Amazon.com Inc <AMZN.O> and
Alphabet Inc <GOOGL.O> rose about 1% in premarket trading ahead
of their results after the closing bell.
Facebook Inc <FB.O>, which also reports later in the day, gained
3.2%, riding on Pinterest Inc's <PINS.N> upbeat forecast for
sales growth that highlighted a rebound in ad spending.
Shares of the image-sharing company soared over 30%, also
driving gains of 2% in Snap Inc <SNAP.N> and 6% in Twitter Inc <TWTR.N>.
Investors will get their first look at third-quarter U.S. GDP
data at 8:30 a.m. ET (1230 GMT), which is likely to show a
record pace of economic expansion fueled by $3 trillion in
federal pandemic relief after a historic slump in the
second-quarter.
A separate report is expected to show the number of Americans
filing for unemployment benefits likely dipped last week but
still remained stubbornly high at 775,000 as boost from the
fiscal aid faded.
Stalled efforts in Washington over fresh stimulus and an
alarming rise in COVID-19 cases globally have put the Wall
Street's main indexes on course for their worst week since
March.
The CBOE volatility index <.VIX> dipped after closing at its
highest level in nearly five months on Wednesday as uncertainty
about a U.S. election outcome next week kept investors on edge.
More than 75 million Americans had already cast ballots in a
historic turnout, with experts predicting a winner may not be
declared on the night of Nov. 3 due to delay in counting mail in
ballots.
Democratic challenger Joe Biden holds a comfortable lead over
President Donald Trump in national polls, but the race in
battleground states that will likely decide the election are
tighter than the national surveys.
At 06:47 a.m. ET, Dow E-minis <1YMcv1> were up 0.5% at 26,554
points and S&P 500 E-minis <EScv1> were up 0.71% at 3,286.75
points. Nasdaq 100 E-minis <NQcv1> were up 0.97% at 11240
points.
Gilead Sciences Inc <GILD.O> slipped 0.8% after it cut its 2020
revenue forecast, citing lower-than-expected demand and
difficulty in predicting sales of remdesivir, the only treatment
approved in the United States for patients hospitalized with
COVID-19.
(Reporting by Medha Singh in Bengaluru; Editing by Anil D'Silva)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|